# Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes

> **NCT05792995** · PHASE2 · COMPLETED · sponsor: **Xin-Hua Xu** · enrollment: 80 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Sindillimab

## Key facts

- **NCT ID:** NCT05792995
- **Lead sponsor:** Xin-Hua Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-21
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05792995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05792995, "Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05792995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*